$INNV lower bollie support 10 day close.
$0.19
Website
Waiting on FDA
approval for over the counter
of #1 sinus med as prescription.
Fluticasone propionate nasal spray
is the #1 most prescribed nasal steroid in the U.S.
since 2007,with more than 150 million units sold .
We currently generate revenues from 17 products in the U.S.
and six in international countries, as follows:
1. Vesele ® for promoting sexual and health (U.S. and U.K.);
2. Zestra ® for female arousal (U.S., U.K., Denmark, Canada, Morocco, and the UAE);
3. Zestra Glide ® (U.S, Canada and the MENA countries);
4. EjectDelay ® indicated for the treatment of premature ejaculation (U.S. and Canada);
5. Sensum+ ® to alleviate reduced penile sensitivity (U.S., U.K. and Morocco);
6. (BeyondHuman) ® Testosterone Booster;
7. BH ® Ketones;
8. BH ® Krill Oil;
9. BH ® Omega 3 Fish Oil;
10. BH ® Vision Formula;
11. BH ® Blood Sugar;
12. BH ® Colon Cleanse;
13. BH ® Green Coffee Extract;
14. BH ® Growth Agent;
15. RecalMax ™ for brain health;
16. Androferti ® (U.S. and Canada) for the support of overall male reproductive health and sperm quality; and
17. UriVarx ™ for overactive bladder and urinary incontinence.
72 % Sell
News
and filings
We are an emerging over-the-counter (" OTC "
consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. We deliver innovative and uniquely presented and packaged health solutions through our (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. We are dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ ANDA ”) products. We are actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC. These “Rx-to-OTC switches” require Food and Drug Administration (“ FDA ”) approval through a process initiated by the New Drug Application (“ NDA ”) holder.
Our business model leverages our ability to (a) develop and build our current pipeline of products and (b) to also acquire outright or in-license commercial products that are supported by scientific and/or clinical evidence, place them through our existing supply chain, retail and on-line (including Amazon®-based business platform) channels to tap new markets and drive demand for such products and to establish physician relationships. We currently market and sell 17 products in the United States with six of those being marketed and sold in multiple countries around the world through some of our 14 commercial partners. We currently expect to launch an additional five products in the United States in 2017 and we currently have approvals to launch certain of our already marketed products in at least three additional countries.
$0.19
Website
Waiting on FDA
approval for over the counter
of #1 sinus med as prescription.
Fluticasone propionate nasal spray
is the #1 most prescribed nasal steroid in the U.S.
since 2007,with more than 150 million units sold .
We currently generate revenues from 17 products in the U.S.
and six in international countries, as follows:
1. Vesele ® for promoting sexual and health (U.S. and U.K.);
2. Zestra ® for female arousal (U.S., U.K., Denmark, Canada, Morocco, and the UAE);
3. Zestra Glide ® (U.S, Canada and the MENA countries);
4. EjectDelay ® indicated for the treatment of premature ejaculation (U.S. and Canada);
5. Sensum+ ® to alleviate reduced penile sensitivity (U.S., U.K. and Morocco);
6. (BeyondHuman) ® Testosterone Booster;
7. BH ® Ketones;
8. BH ® Krill Oil;
9. BH ® Omega 3 Fish Oil;
10. BH ® Vision Formula;
11. BH ® Blood Sugar;
12. BH ® Colon Cleanse;
13. BH ® Green Coffee Extract;
14. BH ® Growth Agent;
15. RecalMax ™ for brain health;
16. Androferti ® (U.S. and Canada) for the support of overall male reproductive health and sperm quality; and
17. UriVarx ™ for overactive bladder and urinary incontinence.
72 % Sell
News
and filings
We are an emerging over-the-counter (" OTC "
consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. We deliver innovative and uniquely presented and packaged health solutions through our (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. We are dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ ANDA ”) products. We are actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC. These “Rx-to-OTC switches” require Food and Drug Administration (“ FDA ”) approval through a process initiated by the New Drug Application (“ NDA ”) holder. Our business model leverages our ability to (a) develop and build our current pipeline of products and (b) to also acquire outright or in-license commercial products that are supported by scientific and/or clinical evidence, place them through our existing supply chain, retail and on-line (including Amazon®-based business platform) channels to tap new markets and drive demand for such products and to establish physician relationships. We currently market and sell 17 products in the United States with six of those being marketed and sold in multiple countries around the world through some of our 14 commercial partners. We currently expect to launch an additional five products in the United States in 2017 and we currently have approvals to launch certain of our already marketed products in at least three additional countries.
